Rosetta Capital

Founded -

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$12M
Portfolio companies 7
Lead investments 1
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.11
Exits 2
Stages of investment
Early Stage Venture

Areas of investment

  • Biopharma
  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
Summary

The main department of described VC is located in the London. The company was established in Europe in United Kingdom.

Among the most successful fund investment fields, there are Medical, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. For fund there is no match between the location of its establishment and the land of its numerous investments - Sweden. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight MerLion Pharma, Dilafor, EyeSense AG.

This Rosetta Capital works on 7 percentage points less the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2019. The real fund results show that this VC is 2 percentage points more often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Rosetta Capital, startups are often financed by Novartis Venture Fund, Kurma Partners, BZ Bank. The meaningful sponsors for the fund in investment in the same round are Praktikerinvest, Ostersju00f6stiftelsen, btov Partners. In the next rounds fund is usually obtained by HealthCap, Versant Ventures, Sectoral Asset Management.

Read more

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Asarina Pharma

Biopharma
Biotechnology
Health Care
Pharmaceutical
Post-IPO Equity
18M20 Sep 2018 Sweden, " Sweden"}

Modus Therapeutics

Biotechnology
Clinical Trials
Pharmaceutical
Therapeutics
Venture - Series Unknown
3M20 Feb 2017 Sweden, Stockholm

Biopharma
Pharmaceutical
6M27 Sep 2016 Sweden, " Sweden"}

NovImmune

Biotechnology
Medical
Pharmaceutical
Early Stage Venture
66M17 Feb 2014 Switzerland, " Switzerland"}

Asarina Pharma

Biopharma
Biotechnology
Health Care
Pharmaceutical
Venture - Series Unknown
08 Mar 2013 Sweden, " Sweden"}

Biosergen AS

Biotechnology
Funding Round
13 Feb 2013 Norway, Trondheim

Aprea

Biotechnology
Health Care
Medical
Personal Health
Pharmaceutical
Early Stage Venture
01 Jan 2013 Sweden, Stockholm

Biotechnology
Pharmaceutical
Late Stage Venture
7M11 Oct 2010 Singapore, Singapore

EyeSense AG

Health Care
Health Diagnostics
Medical
Early Stage Venture
11M10 Feb 2006 Germany, " Germany"}

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Rosetta Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: